Source published October 28, 2026: Duke Department of Neurology institutional announcement. Trial design was checked against NCT07110337, and the device indication was checked against FDA De Novo record DEN240062.
What the study is testing Duke is one of the centers enrolling adults with drug-resistant epilepsy in DETECT, a multicenter study planned for up to 210 participants. The study focuses on people whose seizures were not adequately characterized by prolonged conventional EEG and asks whether months of continuous subscalp recording can help clinicians reach an actionable diagnosis or treatment decision.
The Minder system uses a thin lead with four recording contacts under the scalp. An external wearable and study phone support transfer and storage for physician review. This is monitoring technology, not neurofeedback or brain stimulation.
How the comparison works Participants may choose implantation or standard care. Those who choose the device are then randomized to a group whose treating physician can review the EEG data during follow-up or a blinded group whose data are withheld until the study ends. This means access to device data is randomized within the implanted cohort, while the device-versus-standard-care comparison is not fully randomized.
Why it matters Short EEG recordings can miss infrequent, nocturnal or unwitnessed seizures. Longer observation could give clinicians a more representative view of seizure patterns and treatment response. DETECT is designed to test whether that additional information changes real decisions, rather than assuming that more data automatically improve care.
The important boundaries DETECT is ongoing and has reported no clinical outcomes. Implantation is a procedure with risks that must be assessed individually. FDA granted the Minder system De Novo classification on April 17, 2025 for prescription continuous EEG acquisition, transmission and remote assessment in specified adults with drug-resistant epilepsy. That authorization does not prove that the current trial will improve decisions, symptoms or long-term outcomes.
Funding and interests The trial sponsor is Epiminder America, Inc., the device manufacturer. The Duke announcement does not report independent funding. Commercial sponsorship and the nonrandomized choice of implantation are important when interpreting future results.
Disclosure This is coverage of an institutional trial announcement, not a treatment recommendation or a report of benefit. Prepared with AI assistance; Duke, the trial directory and FDA record were checked October 30, 2026. The image is an AI-generated conceptual illustration with fictional people. It does not show the device, a procedure, measured EEG data or an outcome.